Improving the accuracy of medication adherence measures using linked prescription and dispensation data: findings from the ESOSVAL cohort of patients treated with osteoporosis drugs

References

• Siris ES, Selby PL, Saag KG, et al. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122(Suppl):S3–S13.
   PubMed Web of Science ®Google Scholar
• Imaz I, Zegarra P, González-Enríquez J, et al. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int. 2010;21:1943–1951.
   PubMed Web of Science ®Google Scholar
• Rabenda V, Hiligsmann M, Reginster JY. Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence. Expert Opin Pharmacother. 2009;10:2303–2315.
   PubMed Web of Science ®Google Scholar
• García-Sempere A, Hurtado I, Sanfélix-Genovés J, et al. Primary and secondary non-adherence to osteoporotic medications after hip fracture in Spain. The PREV2FO population-based retrospective cohort study. Sci Rep. 2017;7:11784.
   PubMed Web of Science ®Google Scholar
• Ross S, Samuels E, Gairy K, et al. A meta-analysis of osteoporotic fracture risk with medication nonadherence. Value Health. 2011;14:571–581.
   PubMed Web of Science ®Google Scholar
• Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31–37.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487–497.
   PubMed Web of Science ®Google Scholar
• Brookhart MA, Avorn J, Katz JN, et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med. 2007;120:251–256.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414–2419.
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Winkelmayer WC. Medication adherence after myocardial infarction: a long way left to go. J Gen Intern Med. 2008;23:216–218.
   PubMed Web of Science ®Google Scholar
• Nieuwlaat R, Wilczynski N, Navarro T, et al. Interventions for enhancing medication adherence. Cochrane DB Syst Rev. 2014;20(11):CD000011.
   Google Scholar
• Brown MT, Bussell JK. Medication adherence: who cares? Mayo Clin Proc. 2011;86:304–314.
   PubMed Web of Science ®Google Scholar
• Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care. 2010;48:196–202.
   PubMed Web of Science ®Google Scholar
• Sabaté E. Adherence to long-term therapies: evidence for action [Internet]. Geneva, Switzerland: World Health Organisation; 2003 [cited 2018 Nov 8]. Available from: http://whqlibdoc.who.int/publications/2003/9241545992.pdf
   Google Scholar
• Deshpande S, Quek RG, Forbes CA, et al. A systematic review to assess adherence and persistence with statins. Curr Med Res Opin. 2017;33:769–778.
   PubMed Web of Science ®Google Scholar
• Corrao G, Monzio Compagnoni M, Franchi M, et al. Good adherence to therapy with statins reduces the risk of adverse clinical outcomes even among very elderly. Evidence from an Italian real-life investigation. Eur J Intern Med. 2018;47:25–31.
   PubMed Web of Science ®Google Scholar
• Svedbom A, Hernlund E, Ivergård M, et al. EU Review Panel of IOF. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8:137.
   PubMed Web of Science ®Google Scholar
• Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8:136.
   PubMed Web of Science ®Google Scholar
• Sanfélix-Genovés J, Sanfélix-Gimeno G, Peiró S, et al. Prevalence of osteoporotic fracture risk factors and antiosteoporotic treatments in the Valencia region, Spain. The baseline characteristics of the ESOSVAL cohort. Osteoporos Int. 2013;24:1045–1055.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385–397.
   PubMed Web of Science ®Google Scholar
• Qaseem A, Snow V, Shekelle P, et al. Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2008;149:404–415.
   PubMed Web of Science ®Google Scholar
• Raebel MA, Schmittdiel J, Karter AJ, et al. Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases. Med Care. 2013;51:S11–S21.
   PubMed Web of Science ®Google Scholar
• Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303–2310.
   PubMed Web of Science ®Google Scholar
• Iglay K, Cao X, Mavros P, et al. Systematic literature review and meta-analysis of medication adherence with once-weekly versus once-daily therapy. Clin Ther. 2015;37:1813–1821.e1.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Salas M, Hughes DA, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. Osteoporos Int. 2013;24:2907–2918.
   PubMed Web of Science ®Google Scholar
• Gold DT, Trinh H, Safi W. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Curr Med Res Opin. 2009;25:1831–1839.
   PubMed Web of Science ®Google Scholar
• Netelenbos JC, Geusens PP, Ypma G, et al. Adherence and profile of non-persistence in patients treated for osteoporosis – a large-scale, long-term retrospective study in The Netherlands. Osteoporos Int. 2011;22:1537–1546.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Gold DT, Silverman SL, et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int. 2007;18:1023–1031.
   PubMed Web of Science ®Google Scholar
• Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493–1501.
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013–1022.
   PubMed Web of Science ®Google Scholar
• McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas. 2004;48:271–287.
   PubMed Web of Science ®Google Scholar
• Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116.
   PubMed Web of Science ®Google Scholar
• Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care. 2006;44:471–477.
   PubMed Web of Science ®Google Scholar
• Burden AM, Paterson JM, Gruneir A, et al. Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data. Pharmacoepidemiol Drug Saf. 2015;24:67–74.
   PubMed Web of Science ®Google Scholar